This document summarizes the management of upper gastrointestinal hemorrhage. It discusses risk stratification tools like the Rockall score to determine a patient's risk level. For low risk patients, outpatient care may be appropriate. It also reviews the causes, evaluation, and endoscopic and pharmacologic treatment approaches for acute non-variceal and variceal bleeding.
13. Important History history of oropharyngeal disease anemia weight loss change in bowel habit abdominal pain use of anticoagulation and/or antiplatelet therapy use of nonsteroidal anti-inflammatory drugs including aspirin underlying medical disorder (especially liver disease) previous gastrointestinal surgery previous gastrointestinal disease prior gastrointestinal bleeding age
14. Hemodynamic status and severity of GI bleeding minor <10 Normal Moderate 10-20 Postural (orthostatic hypotension and tachycardia) Massive 20-25 Shock (resting hypotension) Severity of bleed Blood loss (% of intravascular vol) Vital Signs
15.
16.
17. Cappelli MS, et al. High risk gastrointestinal bleeding. Gastroenterol Clin N Am . 2000;29(2) Aljabreen AM, Fallone CA, Barkun AN. Nasogastric aspirate predicts high risk endoscopic lesions in patients with acute upper GI bleeding. Gastrointest Endosc . 2004;59:172. 28.7 Red 19.4 Brown 12.3 Black Red Blood 19.1 Red 8.2 Brown or black Coffee ground 6 Brown or Red Clear Mortality % Stool color NG aspirate color
19. The Rockall risk score scheme Rockall Score > 2 High Risk Maximum additive score prior to diagnosis=7, maximum additive score following diagnosis=11. BP, blood pressure; SRH, stigmata of recent hemorrhage - Blood in upper gastrointestinal tract, adherent clot, visible or spurting vessel - None or dark spot only Major stigmata of recent hemorrhage - Malignancy of upper gastrointestinal tract All other diagnoses Mallory-Weiss tear, no lesion identified and no SRH Diagnosis Renal failure, liver failure, disseminated malignancy Cardiac failure, ischemic heart disease, any major comorbidity - No major comorbidity Comorbidity - Hypotension (systolic BP<100) Tachycardia (systolic BP 100, pulse>100) No shock (systolic BP 100, pulse<100) Shock - >80 60-79 <60 Age (years) 3 2 1 0 Score Value
20. Rockall score < 2 could be safely managed in OPD setting Rockall T, Logan R, Devlin H, et al. Selection of patients for early discharged or outpatient care after acute gastrointestinal hemorrhage. Lancet . 1996;347:1138-40.
21.
22.
23.
24.
25. Blantchford Score Blantchford score > 0 High Risk 6 < 10 1 10 - 12 g / dL Hemoglobin level for women ( g / dL ) 6 < 10 3 10 - 11 g / dL 1 12 - 13 g / dL Hemoglobin level for men ( g / dL ) 6 > 70 4 > 28 - 70 3 > 22.4 - 28 2 > 18.2 – 22.4 Blood urea nitrogen level ( mg / dL ) Score Admission risk marker 2 Cardiac failure 2 Hepatic disease 2 Presentation with syncope 1 Presentation with melena 1 Pulse > 100 per min Other markers 3 <90 2 90 - 99 1 100 -109 Systolic blood pressures ( mm Hg ) Score Admission risk marker
26. The Rockall risk score scheme Clinical Rockall Score Maximum additive score prior to diagnosis=7, maximum additive score following diagnosis=11. BP, blood pressure; SRH, stigmata of recent hemorrhage - Blood in upper gastrointestinal tract, adherent clot, visible or spurting vessel - None or dark spot only Major stigmata of recent hemorrhage - Malignancy of upper gastrointestinal tract All other diagnoses Mallory-Weiss tear, no lesion identified and no SRH Diagnosis Renal failure, liver failure, disseminated malignancy Cardiac failure, ischemic heart disease, any major comorbidity - No major comorbidity Comorbidity - Hypotension (systolic BP<100) Tachycardia (systolic BP 100, pulse>100) No shock (systolic BP 100, pulse<100) Shock - >80 60-79 <60 Age (years) 3 2 1 0 Score Value
27. Clinical Rockall score 0, no adverse outcomes 1-3,no adverse outcomes, 29% need transfusion >3 ,21% rebleeding, 5%surgery, 10% death OPD workup Tham TCK, James C, Kelly M. Predicting outcome of acute non variceal upper gastrointestinal hemorrhage without endoscopy using clinical Rockall score. Postgrad Med J 2006;82:757-759. Clinical Rockall < 3
29. High Risk factors Host factors: Age > 60 yrs Cormorbid conditions Hemostatic instability,orthostatic hypotension, PR> 100,BP < 100 Coagulopathy Bleeding character: Continuous red blood from NG Red blood per rectum Patient course: Need blood transfusion Hemodynamic instability
36. Omeprazole before endoscopy in patients with gastrointestinal bleedings Lau JY, Leung WK, Wu JC, et al. New Engl J Med . 2007 Apr 19;356(16): 1631-40. N 638 319 319 Omeprazole 80mgIV bolus, 8mg/hr placebo 19.1% 28.4% Endoscopic Rx
37. Reduced the need for endoscopic therapy Infusion of high dose Omeprazole before endoscopy acclerated the resolution of signs of bleeding in ulcers Lau JY, Leung WK, Wu JC, et al. New Engl J Med . 2007 Apr 19;356(16): 1631-40 .
42. 72 >16 50 >15-16 17 >14-15 9 >13-14 0 < 13 Incidence of bleeding % Variceal Pressure mm Hg
43.
44. Predicting Variceal Hemorrhage 72 60 44 52 40 28 34 23 16 +++ 54 38 28 33 23 15 19 12 8 + 42 30 20 26 16 10 15 10 6 - F3 F2 F1 F3 F2 F1 F3 F2 F1 C B A Red Wale Child Class
45. Risk Factors for recurrent hemorrhage Platelet clot on varice Red signs Red signs Active Bleeding on scope Active alcoholism Ascites Hepatoma Renal failure Ascites Severity of initial bleed Severity of liver failure Age > 60 Late Rebleeding >6wk Early Rebleeding <6wk
46. Sherry red spot (red color sign) Red Spot Red Wale sign (varices on varix)
49. N-2 butyl-cyanoacrylate for bleeding gastric varices: A United states pilot study and cost analysis Greenwald BD, Caldwell SH, Hespenheide EE, et al Am J Gastroenterol 2003 Sep;98(9):1982-8. Odd of Death > 7 fold non cyanoacrylate group 5/28 (18%) 1 year 1/30 (3%) 6 week 2/37 (5.5%) 72 hour Rebleeding 24/31 (29%) 1 year 30/34 (88%) 3 months survival